MARKETS / NYSE / ABBV

NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

AbbVie Inc. ABBV

15 fiscal years on record · USD · FY2025 reported · SEC filings only

11 YEARS OF DIVIDEND GROWTH

Revenue

$61.2B

▲ 8.6% YoY

Net income

$4.2B

▼ 1.2% YoY

Free cash flow

$17.8B

▼ 0.1% YoY

In brief

What this company does

AbbVie develops, manufactures, commercializes and sells medicines and therapies, operating as a single global business segment. It employed approximately 57,000 employees in over 70 countries as of December 31, 2025. In 2025, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of its pharmaceutical product sales in the United States. Its product portfolio spans immunology, neuroscience, oncology and aesthetics. In immunology, the company maintains a portfolio across rheumatology, dermatology and gastroenterology. The Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring and skincare products. Incorporated in Delaware on April 10, 2012, AbbVie became an independent, publicly traded company on January 1, 2013, when Abbott Laboratories distributed 100% of the outstanding common stock of AbbVie to Abbott's shareholders.

Written from the business description in AbbVie Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 20 February 2026. Every sentence was checked against that document before publication.

Growth

USD 61.2B

Revenue, FY2025 · full 15-year series below

Revenue $B Net income $B

FY2025 · Revenue 61.2 · Net income 4.2

Compound annual growth

Revenue

+1.8%

+6.0%

+10.3%

Net income

−29.1%

−1.7%

−1.9%

EPS, diluted

−29.1%

−2.8%

Dividend / share

+5.2%

+6.6%

+12.2%

Returned to shareholders

+3.4%

+8.0%

+1.5%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +6.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

7 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 24.6% · Net 6.9%

ROE

FY2025 · ROE 15367.3%

Gross margin70.2%

Operating margin24.6%

Net margin6.9%

Return on assets3.1%

EBITDAUSD 15.8B

Each USD of equity produced 15367 cents of profit this year.

Cash & shareholders

USD 12.5B

returned in FY2025 · dividends + net buybacks

Free cash flow $B

FY2025 · FCF 17.8

Net buybacks $B Dividends $B

FY2025 · Dividends 11.7 · Net buybacks 0.8

Dividends paidUSD 11.7B

Net buybacksUSD 808.0M

Share of profit295.0%

Consecutive raises11 years

USD 11.7B in dividends and USD 808.0M in buybacks — 295% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 134.0B

EquityUSD -3.3B

CashUSD 5.2B

Gross debtUSD 67.0B

Net debtUSD 61.8B

Current ratio0.67×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 15-year record

15 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue $B	61.2	56.3	54.3	58.1	56.2	45.8	33.3	32.8	28.2	25.6	22.9	20.0	18.8	18.4	17.4
Operating income $B	15.1	9.1	12.8	18.1	17.9	11.4	13.0	6.4	9.5	9.3	7.5	3.4	5.7	5.8	3.6
EBITDA $B	15.8	9.9	13.5	18.9	18.7	12.0	13.4	6.9	10.0	9.8	8.0	3.8	6.1	6.3	4.1
Income tax $B	2.4	−0.6	1.4	1.6	1.4	−1.2	0.5	−0.5	2.4	1.9	1.5	0.6	1.2	0.5	0.2
Net income $B	4.2	4.3	4.9	11.8	11.5	4.6	7.9	5.7	5.3	6.0	5.1	1.8	4.1	5.3	3.4
Free cash flow $B	17.8	17.8	22.1	24.2	22.0	16.8	12.8	12.8	9.4	6.6	7.0	2.9	5.8	6.0	5.9
EPS, diluted $	2.36	2.39	2.72	6.63	6.45	2.72	5.28	3.66	3.30	3.63	3.13	1.10	2.56	3.35	2.18
Dividend / sh $	6.65	6.29	5.99	5.71	5.31	4.84	4.39	3.95	2.63	2.35	2.10	1.75	2.00	·	·
Payout %	276	258	217	85	80	167	81	98	77	62	64	150	62	·	·
ROE %	15367.3	62.5	35.2	72.5	81.0	188.3	·	·	109.1	138.7	180.9	56.9	199.3	·	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

AbbVie Inc.vsJohnson & JohnsonSame industry: Pharmaceutical Preparations AbbVie Inc.vsELI Lilly & Co.Same industry: Pharmaceutical Preparations AbbVie Inc.vsMerck & Co. Inc.Same industry: Pharmaceutical Preparations AbbVie Inc.vsPfizer Inc.Same industry: Pharmaceutical Preparations AbbVie Inc.vsAstrazeneca PLCSame industry: Pharmaceutical Preparations AbbVie Inc.vsNovartis AGSame industry: Pharmaceutical Preparations AbbVie Inc.vsBristol Myers Squibb Co.Same industry: Pharmaceutical Preparations

Provenance

Company facts, as filed

How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 22 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityPharmaceutical Preparations

Listed onNYSE

Incorporated inDelaware

Fiscal year endsDecember 31

Data on record since2011